|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZZEF1 |
Gene summary for ZZEF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZZEF1 | Gene ID | 23140 |
| Gene name | zinc finger ZZ-type and EF-hand domain containing 1 | |
| Gene Alias | ZZZ4 | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | O43149 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23140 | ZZEF1 | LZE24T | Human | Esophagus | ESCC | 2.66e-11 | 3.02e-01 | 0.0596 |
| 23140 | ZZEF1 | P1T-E | Human | Esophagus | ESCC | 5.79e-10 | 3.25e-01 | 0.0875 |
| 23140 | ZZEF1 | P2T-E | Human | Esophagus | ESCC | 8.67e-17 | 1.99e-01 | 0.1177 |
| 23140 | ZZEF1 | P5T-E | Human | Esophagus | ESCC | 2.69e-05 | 4.02e-02 | 0.1327 |
| 23140 | ZZEF1 | P8T-E | Human | Esophagus | ESCC | 1.63e-24 | 2.95e-01 | 0.0889 |
| 23140 | ZZEF1 | P9T-E | Human | Esophagus | ESCC | 2.13e-04 | 1.42e-01 | 0.1131 |
| 23140 | ZZEF1 | P10T-E | Human | Esophagus | ESCC | 7.85e-19 | 2.04e-01 | 0.116 |
| 23140 | ZZEF1 | P11T-E | Human | Esophagus | ESCC | 8.25e-08 | 3.23e-01 | 0.1426 |
| 23140 | ZZEF1 | P12T-E | Human | Esophagus | ESCC | 5.25e-23 | 1.95e-01 | 0.1122 |
| 23140 | ZZEF1 | P16T-E | Human | Esophagus | ESCC | 5.55e-14 | 2.13e-01 | 0.1153 |
| 23140 | ZZEF1 | P17T-E | Human | Esophagus | ESCC | 2.72e-08 | 3.19e-01 | 0.1278 |
| 23140 | ZZEF1 | P20T-E | Human | Esophagus | ESCC | 3.42e-10 | 1.98e-01 | 0.1124 |
| 23140 | ZZEF1 | P21T-E | Human | Esophagus | ESCC | 9.38e-18 | 2.23e-01 | 0.1617 |
| 23140 | ZZEF1 | P22T-E | Human | Esophagus | ESCC | 2.76e-13 | 1.62e-01 | 0.1236 |
| 23140 | ZZEF1 | P23T-E | Human | Esophagus | ESCC | 9.25e-09 | 1.88e-01 | 0.108 |
| 23140 | ZZEF1 | P24T-E | Human | Esophagus | ESCC | 1.91e-06 | 1.16e-01 | 0.1287 |
| 23140 | ZZEF1 | P26T-E | Human | Esophagus | ESCC | 1.07e-09 | 1.30e-01 | 0.1276 |
| 23140 | ZZEF1 | P27T-E | Human | Esophagus | ESCC | 9.35e-21 | 2.42e-01 | 0.1055 |
| 23140 | ZZEF1 | P28T-E | Human | Esophagus | ESCC | 1.53e-18 | 2.63e-01 | 0.1149 |
| 23140 | ZZEF1 | P30T-E | Human | Esophagus | ESCC | 5.78e-22 | 4.65e-01 | 0.137 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZZEF1 | SNV | Missense_Mutation | novel | c.5782A>G | p.Thr1928Ala | p.T1928A | O43149 | protein_coding | tolerated(0.65) | benign(0) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ZZEF1 | SNV | Missense_Mutation | rs546462540 | c.724N>C | p.Glu242Gln | p.E242Q | O43149 | protein_coding | tolerated(0.12) | probably_damaging(0.959) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZZEF1 | SNV | Missense_Mutation | c.889N>A | p.Val297Met | p.V297M | O43149 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZZEF1 | SNV | Missense_Mutation | rs756019778 | c.920C>G | p.Ala307Gly | p.A307G | O43149 | protein_coding | deleterious(0.03) | benign(0.243) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZZEF1 | SNV | Missense_Mutation | novel | c.6900N>A | p.Asp2300Glu | p.D2300E | O43149 | protein_coding | tolerated(0.05) | possibly_damaging(0.893) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
| ZZEF1 | SNV | Missense_Mutation | c.2885N>T | p.Ser962Phe | p.S962F | O43149 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ZZEF1 | SNV | Missense_Mutation | c.5018N>G | p.Ala1673Gly | p.A1673G | O43149 | protein_coding | deleterious(0.01) | probably_damaging(0.931) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ZZEF1 | SNV | Missense_Mutation | c.2156N>A | p.Cys719Tyr | p.C719Y | O43149 | protein_coding | tolerated(0.2) | benign(0.345) | TCGA-BH-A1FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZZEF1 | SNV | Missense_Mutation | c.8689N>A | p.Arg2897Ser | p.R2897S | O43149 | protein_coding | deleterious(0.04) | possibly_damaging(0.907) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| ZZEF1 | SNV | Missense_Mutation | c.3781N>C | p.Glu1261Gln | p.E1261Q | O43149 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-EW-A1IX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |